Management and Outcomes of Clostridioides difficile Infection in Patients on Immune Checkpoint Inhibitors.|https://dx.doi.org/10.6004/jnccn.2024.7355
More questions than answers? Predicting FMT outcomes for recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.cmi.2025.04.036
Evaluation of the Efficacy of Step-down Therapy with Oral Minocycline for Complicated Pyelonephritis Caused by Extended-Spectrum Î²-Lactamase-Producing Enterobacterales: A Retrospective Cohort Study.|https://dx.doi.org/10.1016/j.jiac.2025.102724
Beyond Random Fecal Microbial Transplants: Next Generation Personalized Approaches to Normalize Dysbiotic Microbiota for Treating IBD.|https://dx.doi.org/10.1016/j.gtc.2024.11.002
Current Approaches to Treat and Prevent Recurrence of Clostridioides difficile.|https://dx.doi.org/10.1016/j.gtc.2025.02.005
Bacterial diversity, viability and stability in lyophilised faecal microbiota capsules support ongoing clinical use.|https://dx.doi.org/10.1016/j.ijpharm.2025.125703
Reactive Arthritis.|https://dx.doi.org/10.12890/2025_005350
